GB9317987D0
(en)
*
|
1993-08-26 |
1993-10-13 |
Glaxo Group Ltd |
Chemical compounds
|
IS4208A
(is)
*
|
1993-09-22 |
1995-03-23 |
Glaxo Group Limited |
3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
|
JP3925662B2
(ja)
*
|
1995-01-12 |
2007-06-06 |
グラクソ,グループ,リミテッド |
タキキニンアンタゴニスト活性を有するピペリジン誘導体
|
GB9505692D0
(en)
*
|
1995-03-21 |
1995-05-10 |
Glaxo Group Ltd |
Chemical compounds
|
GB9513117D0
(en)
*
|
1995-06-28 |
1995-08-30 |
Merck Sharp & Dohme |
Therapeutic agents
|
TW458774B
(en)
|
1995-10-20 |
2001-10-11 |
Pfizer |
Antiemetic pharmaceutical compositions
|
US6211199B1
(en)
|
1995-11-17 |
2001-04-03 |
Aventis Pharmaceuticals Inc. |
Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
|
GB9525296D0
(en)
*
|
1995-12-11 |
1996-02-07 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5922737A
(en)
*
|
1996-02-21 |
1999-07-13 |
Hoechst Marion Roussel, Inc. |
Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
|
US5932571A
(en)
*
|
1996-02-21 |
1999-08-03 |
Hoechst Marion Roussel, Inc. |
Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
|
US5998439A
(en)
*
|
1996-02-21 |
1999-12-07 |
Hoescht Marion Roussel, Inc. |
Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
|
JP2000514047A
(ja)
*
|
1996-06-26 |
2000-10-24 |
ワーナー―ランバート・コンパニー |
催吐の処置用医薬の製造のためのタキキニンアンタゴニストの使用
|
MX9706196A
(es)
*
|
1996-08-14 |
1998-02-28 |
Pfizer |
Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
|
MX9706944A
(es)
*
|
1996-09-12 |
1998-08-30 |
Pfizer |
Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
|
US6117855A
(en)
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
WO1998024439A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating severe anxiety disorders
|
CA2273807A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating schizophrenic disorders
|
CA2273853A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating cognitive disorders
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
EP0941093B1
(en)
*
|
1996-12-02 |
2005-02-09 |
MERCK SHARP & DOHME LTD. |
Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
|
JP2001507678A
(ja)
*
|
1996-12-02 |
2001-06-12 |
メルク シヤープ エンド ドーム リミテツド |
運動障害の治療のためのnk−1受容体拮抗薬の使用
|
US6613765B1
(en)
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
EP0942729B1
(en)
*
|
1996-12-02 |
2004-09-01 |
MERCK SHARP & DOHME LTD. |
Use of nk-1 receptor antagonists for treating stress disorders
|
CA2273856A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating bipolar disorders
|
JP2001504853A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
物質使用障害の治療のためのnk−1受容体拮抗薬の使用
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
AU733855B2
(en)
*
|
1996-12-02 |
2001-05-31 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
JP2001504851A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
性的機能不全の治療のためのnk−1受容体拮抗薬の使用
|
US5861417A
(en)
*
|
1996-12-19 |
1999-01-19 |
Hoechst Marion Roussel, Inc. |
Heterocyclic substituted pyrrolidine amide derivatives
|
EP0977572A1
(en)
*
|
1997-04-24 |
2000-02-09 |
Merck Sharp & Dohme Ltd. |
Use of nk-1 receptor antagonists for treating eating disorders
|
JP2002506459A
(ja)
|
1997-06-27 |
2002-02-26 |
メルク シヤープ エンド ドーム リミテツド |
置換された3−(ベンジルアミノ)ピペリジン誘導体およびその治療薬としての使用
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
AU738047B2
(en)
*
|
1997-08-04 |
2001-09-06 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating mania
|
WO1999007375A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
|
GB9723544D0
(en)
*
|
1997-11-07 |
1998-01-07 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
US6271230B1
(en)
|
1997-12-01 |
2001-08-07 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
US6156749A
(en)
*
|
1997-12-01 |
2000-12-05 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating movement disorders
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
ATE434437T1
(de)
*
|
1999-02-18 |
2009-07-15 |
Novasearch Ag |
Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
|
JP2001039954A
(ja)
*
|
1999-05-24 |
2001-02-13 |
Tomono Agrica Co Ltd |
ヘテロ環誘導体
|
AU2001292320A1
(en)
*
|
2000-10-02 |
2002-04-15 |
Tanabe Seiyaku Co., Ltd. |
Benzylamine compound, process for producing the same, and intermediate therefor
|
US7498332B2
(en)
|
2001-02-14 |
2009-03-03 |
Duke University |
Therapy for cerebral vasospasm
|
US20040142929A1
(en)
*
|
2001-07-06 |
2004-07-22 |
Ramon Merce-Vidal |
Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
|
US20030083345A1
(en)
*
|
2001-07-10 |
2003-05-01 |
Torsten Hoffmann |
Method of treatment and/or prevention of brain, spinal or nerve injury
|
AU2003284975B2
(en)
*
|
2002-10-30 |
2009-04-02 |
Merck Sharp & Dohme Corp. |
Heteroarylpiperidine modulators of chemokine receptor activity
|
GB0308968D0
(en)
*
|
2003-04-17 |
2003-05-28 |
Glaxo Group Ltd |
Medicaments
|
JP4710608B2
(ja)
*
|
2003-08-01 |
2011-06-29 |
東洋紡績株式会社 |
アルコキシ−テトラゾール−1−イル−ベンズアルデヒド化合物およびその製造方法
|
CN1580283A
(zh)
*
|
2003-08-13 |
2005-02-16 |
清华大学 |
一种检测核酸分子的方法
|
WO2005051919A1
(en)
*
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
GB0409098D0
(en)
*
|
2004-04-23 |
2004-05-26 |
Glaxo Group Ltd |
Medicament
|
ZA200701232B
(en)
|
2004-07-15 |
2008-08-27 |
Amr Technology Inc |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
|
JP2006137691A
(ja)
*
|
2004-11-11 |
2006-06-01 |
Toyo Kasei Kogyo Co Ltd |
2−アルコキシ−5−テトラゾリル−ベンズアルデヒド化合物の製造方法
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
EP1904069B1
(en)
|
2005-07-15 |
2018-06-13 |
Albany Molecular Research, Inc. |
Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
US8293900B2
(en)
|
2005-09-29 |
2012-10-23 |
Merck Sharp & Dohme Corp |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
BRPI0806245B1
(pt)
|
2007-01-10 |
2022-01-25 |
Msd Italia S.R.L. |
Compostos de fórmula i e seus usos
|
KR20090112722A
(ko)
|
2007-01-24 |
2009-10-28 |
글락소 그룹 리미티드 |
3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 r(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 nk1을 포함하는 제약 조성물
|
CA2682727C
(en)
|
2007-04-02 |
2016-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Indoledione derivative
|
US7858666B2
(en)
*
|
2007-06-08 |
2010-12-28 |
Mannkind Corporation |
IRE-1α inhibitors
|
EP2170076B1
(en)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US8598184B2
(en)
|
2008-03-03 |
2013-12-03 |
Tiger Pharmatech |
Protein kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
MX2010014461A
(es)
*
|
2008-06-24 |
2011-04-28 |
Valeant Pharmaceuticals Int |
Derivados de benciloxi anilida utiles como moduladores de canales de potasio.
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
CA2760837C
(en)
|
2009-05-12 |
2018-04-03 |
Albany Molecular Research, Inc. |
7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
|
CN102638982B
(zh)
|
2009-05-12 |
2015-07-08 |
百时美施贵宝公司 |
(S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
|
KR20120034644A
(ko)
|
2009-05-12 |
2012-04-12 |
알바니 몰레큘라 리써치, 인크. |
아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
WO2012024170A2
(en)
|
2010-08-17 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
JP2014514321A
(ja)
|
2011-04-21 |
2014-06-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
インスリン様増殖因子1受容体阻害剤
|
EP2729147B1
(en)
|
2011-07-04 |
2017-09-06 |
IRBM - Science Park S.p.A. |
Nk-1 receptor antagonists for treating corneal neovascularisation
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
MX363243B
(es)
|
2012-11-28 |
2019-03-14 |
Merck Sharp & Dohme |
Composiciones para tratar cáncer y usos de dichas composiciones.
|
RU2690663C2
(ru)
|
2012-12-20 |
2019-06-05 |
Мерк Шарп И Доум Корп. |
Замещенные имидазопиридины в качестве ингибиторов hdm2
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
MX2019015150A
(es)
|
2017-06-30 |
2020-08-13 |
Chase Therapeutics Corp |
Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión.
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
RU2020131446A
(ru)
|
2018-02-26 |
2022-03-28 |
Оспедале Сан Раффаэле С.Р.Л. |
Антагонисты nk-1 для применения в лечении глазной боли
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833668A4
(en)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
PRMT5 INHIBITORS
|
EP4117673A1
(en)
|
2020-03-11 |
2023-01-18 |
Ospedale San Raffaele S.r.l. |
Treatment of stem cell deficiency
|